Donaldson Mark T, LaMonte Bernadette H, Morresey Peter, Smith Gary, Beech Jill
Department of Clinical Studies-New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA.
J Vet Intern Med. 2002 Nov-Dec;16(6):742-6. doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2.
Medical records of 27 horses (including 13 ponies) treated with pergolide or cyproheptadine for pituitary pars intermedia dysfunction were reviewed to determine the effect of treatment on plasma ACTH, insulin, and glucose concentrations and clinical signs. Prior to treatment, the most common clinical signs were laminitis, hirsutism, and abnormal body fat distribution. The median pergolide dose was 3.0 microg/kg p.o. q24h (range, 1.7-5.5 microg/kg). All horses treated with cyproheptadine were given 0.25 mg/kg p.o. q24h. After pergolide treatment, ACTH concentrations (n = 20; median = 30.4 pg/ml; range, 4.2-173) were significantly lower (P < .01) than those in horses treated with cyproheptadine (n = 7; median = 141.0 pg/ml: range, 10-1,230). Among horses treated with pergolide, there was a correlation between ACTH concentration after treatment and the duration of treatment (P < .001) and pergolide dose (P = .04). Significantly (P = .02) more owners of horses treated with pergolide (85%, 17/20) reported an improvement in clinical signs compared to owners of horses treated with cyproheptadine (28%, 2/7).
回顾了27匹马（包括13匹小马）使用培高利特或赛庚啶治疗垂体中间部功能障碍的病历，以确定治疗对血浆促肾上腺皮质激素（ACTH）、胰岛素和葡萄糖浓度以及临床症状的影响。治疗前，最常见的临床症状是蹄叶炎、多毛症和异常体脂分布。培高利特的中位剂量为3.0微克/千克口服，每24小时一次（范围为1.7 - 5.5微克/千克）。所有接受赛庚啶治疗的马均给予0.25毫克/千克口服，每24小时一次。培高利特治疗后，ACTH浓度（n = 20；中位数 = 30.4皮克/毫升；范围为4.2 - 173）显著低于（P <.01）接受赛庚啶治疗的马（n = 7；中位数 = 141.0皮克/毫升；范围为10 - 1230）。在接受培高利特治疗的马中，治疗后ACTH浓度与治疗持续时间（P <.001）和培高利特剂量（P =.04）之间存在相关性。与接受赛庚啶治疗的马的主人（28%，2/7）相比，接受培高利特治疗的马的主人（85%，17/20）报告临床症状改善的比例显著更高（P =.02）。
